Abivax S.A. — Investor Relations & Filings
Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms. The company's core strategy revolves around modulating the immune response through microRNA (miRNA). Its lead drug candidate, obefazimod, is an investigational, orally administered small molecule with a novel mechanism of action. Obefazimod is designed to enhance the expression of miR-124, a key microRNA that regulates the inflammatory response. The primary development goal is the commercialization of obefazimod for the treatment of ulcerative colitis, with clinical programs also underway for Crohn's disease. The company is exploring obefazimod for other inflammatory indications and is investigating follow-on compounds from its proprietary chemical library.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 6-K | 2026-05-22 | English | |
| 6-K | 2026-05-20 | English | |
| 6-K - Abivax S.A. (0001956827) (Filer) | 2026-05-07 | English | |
| 424B7 - Abivax S.A. (0001956827) (Filer) | 2026-05-07 | English | |
| S-8 - Abivax S.A. (0001956827) (Filer) | 2026-03-23 | English | |
| 20-F - Abivax S.A. (0001956827) (Filer) | 2026-03-23 | English |
Browse filings by year
5 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
10 filings
| |||||
| 46859106 | 6-K | 2026-05-22 | English | ||
| 46692793 | 6-K | 2026-05-20 | English | ||
| 43481539 | 6-K - Abivax S.A. (0001956827) (Filer) | 2026-05-07 | English | ||
| 43132807 | 424B7 - Abivax S.A. (0001956827) (Filer) | 2026-05-07 | English | ||
| 33016665 | S-8 - Abivax S.A. (0001956827) (Filer) | 2026-03-23 | English | ||
| 33016505 | 20-F - Abivax S.A. (0001956827) (Filer) | 2026-03-23 | English | ||
| 33016424 | 6-K - Abivax S.A. (0001956827) (Filer) | 2026-03-23 | English | ||
| 32249312 | SCHEDULE 13G/A Filing | 2026-02-13 | English | ||
| 13630008 | Major Shareholding Notification 2026 | 2026-01-14 | English | ||
| 13630005 | Regulatory Filings 2026 | 2026-01-08 | English | ||
|
2025
5 filings
| |||||
| 13630007 | 6-K | 2025-12-15 | English | ||
| 13630010 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 13630009 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 13630012 | Major Shareholding Notification 2025 | 2025-10-30 | English | ||
| 13630011 | Regulatory Filings 2025 | 2025-10-28 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
C4 Therapeutics, Inc.
Clinical-stage biopharma developing targeted protein degrad…
|
CCCC | US | Manufacturing |
|
Cadrenal Therapeutics, Inc.
A late-stage biopharmaceutical company developing novel ant…
|
CVKD | US | Manufacturing |
|
CalciMedica, Inc.
Develops CRAC channel inhibitors for acute inflammatory and…
|
CALC | US | Manufacturing |
|
Calidi Biotherapeutics, Inc.
Develops stem cell platforms to deliver oncolytic viruses f…
|
CLDI | US | Manufacturing |
|
Calliditas Therapeutics
Biopharma company developing and commercializing treatments…
|
CALTX | SE | Manufacturing |
|
Callitas Health Inc.
Clinical-stage biomedical company developing pharma and OTC…
|
MPHMF | CA | Manufacturing |
|
CALTH. Inc
Develops in vitro diagnostic tools for point-of-care and se…
|
402420 | KR | Manufacturing |
|
Cambrex
A CDMO providing drug substance, drug product, and analytic…
|
CBM | US | Manufacturing |
|
CAMBRIDGE NUTRITIONAL SCIENCES PLC
Develops and manufactures diagnostic tests for food sensiti…
|
CNSL | GB | Manufacturing |
|
Camp4 Therapeutics Corp
Develops RNA-based therapeutics to amplify protein expressi…
|
CAMP | US | Manufacturing |
Abivax S.A. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/30868/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=30868 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=30868 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=30868 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 30868}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Abivax S.A. (id: 30868)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.